Delcath Systems (DCTH) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Delcath Systems (DCTH) is set to announce its Q2 2025 earnings on Wednesday, August 6th, with expectations of earnings of $0.02 per share and revenue of $22.84 million.
• In its previous earnings report, Delcath Systems reported $0.03 EPS, missing estimates, and had a negative return on equity of 29.44% and net margin of 26.38%.
• Analysts have varying ratings for the stock, with HC Wainwright maintaining a "buy" rating and a price target of $29, while the average rating stands at "Moderate Buy" with a target of $24.00.

Delcath Systems (NASDAQ:DCTH - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Delcath Systems to post earnings of $0.02 per share and revenue of $22.84 million for the quarter.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. The business had revenue of $19.80 million for the quarter, compared to analysts' expectations of $16.83 million. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Delcath Systems Stock Performance

Shares of DCTH stock traded up $0.02 on Wednesday, reaching $10.93. 461,429 shares of the company's stock traded hands, compared to its average volume of 693,316. Delcath Systems has a 12-month low of $7.17 and a 12-month high of $18.23. The company has a market capitalization of $380.69 million, a P/E ratio of -21.86 and a beta of 0.87. The business's 50 day moving average price is $13.89 and its two-hundred day moving average price is $13.78.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $29.00 price target (up previously from $24.00) on shares of Delcath Systems in a report on Friday, May 23rd. Wall Street Zen lowered Delcath Systems from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Stephens reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Delcath Systems in a research report on Monday, June 23rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Delcath Systems currently has a consensus rating of "Moderate Buy" and an average price target of $24.00.

Institutional Trading of Delcath Systems

A hedge fund recently raised its stake in Delcath Systems stock. Goldman Sachs Group Inc. raised its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 58.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 123,487 shares of the company's stock after acquiring an additional 45,695 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.35% of Delcath Systems worth $1,572,000 as of its most recent filing with the SEC. Institutional investors own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.